Timothy P. Reilly

Executive Director, Immuno-Oncology, Bristol-Myers Squibb

In addition to being the father of a child with SMA, Tim is co-founder, vice chair and chief scientific officer of the Spinal Muscular Atrophy Research Team (SMART), a small, not-for-profit organization dedicated to funding biomedical research aimed at finding a cure for SMA and related neuromuscular diseases. He is also a member of the Translational Research Council (TAC) for the Families of Spinal Muscular Atrophy (FSMA). Professionally, Tim is a Director within R&D at Bristol-Myers Squibb Company in Princeton, New Jersey, where he is the Therapeutic Area Head for Metabolic Diseases within the Drug Safety organization and Exploratory Development Team leader for several programs in early development that span therapeutic areas.

Untapped Drug Development Opportunities Abound

Orphan diseases used to be a lonely place in drug development, but with recent analyses showing high profitability potential, support from disease advocacy organizations, and new therapeutic approaches, biopharmaceutical companies are beginning to embrace rare diseases, including Spinal Muscular Atrophy.

Timothy P. Reilly